C430003P19Rik Activators
C430003P19Rik Activators would be a term applied to molecules that specifically increase the activity of the protein encoded by the gene C430003P19Rik. The process of discovering and developing activators for a given protein typically involves a multifaceted approach, beginning with high-throughput screening (HTS). This process utilizes automated platforms to test a large library of chemical compounds for their ability to modulate protein function. In the case of C430003P19Rik, the HTS assays would be designed to detect an upregulation in the protein's activity. These assays often employ reporter systems that can include changes in fluorescence or luminescence to indicate protein activity. Such systems enable rapid quantification and identification of compounds that can enhance the activity of C430003P19Rik. Those molecules that show a significant and reproducible increase in activity are then selected for more thorough validation through secondary assays. These secondary assays are crucial as they confirm the activator's specific action on the protein, eliminating any false positives that may have arisen due to non-specific effects or artifacts of the initial screening process.
Once a compound has been validated as a genuine activator of C430003P19Rik, it then undergoes detailed mechanistic studies to understand the interaction with the target protein. Structural analysis techniques, such as X-ray crystallography or nuclear magnetic resonance spectroscopy (NMR), can provide high-resolution images of the protein in complex with the activator molecule, revealing how the activator binds to the protein and induces an increase in activity. This structural information is vital for understanding the precise molecular interactions that lead to activation. Additionally, biophysical assays like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are employed to measure the binding kinetics and affinity between the C430003P19Rik protein and its activators.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate binds to its receptors, initiating signaling cascades that can lead to the activation of downstream effectors that modulate the signaling processes in which C430003P19Rik is involved, thereby indirectly enhancing C430003P19Rik activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), causing an increase in cytosolic calcium levels. This calcium influx can activate calcium-dependent signaling pathways that may enhance the functional activity of C430003P19Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can phosphorylate and modulate various signaling molecules. PKC-mediated phosphorylation events can lead to the enhancement of C430003P19Rik activity within its associated signaling networks. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can alter PI3K/AKT pathway signaling. As PI3K/AKT can regulate numerous cellular processes, inhibition by LY294002 may result in a compensatory enhancement of alternative pathways, potentially involving C430003P19Rik activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that impedes the MAPK/ERK pathway. By inhibiting MEK, U0126 might enhance signaling through parallel pathways or reduce negative feedback loops, which could lead to the indirect activation of C430003P19Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which might shift signaling dynamics to pathways not reliant on p38 MAPK activity. This could result in the indirect enhancement of C430003P19Rik activity by favoring its signaling pathways over those inhibited by SB203580. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a broad inhibitor of various kinases. By inhibiting certain kinases, it may relieve inhibitory phosphorylation events on signaling partners of C430003P19Rik, indirectly enhancing the functional activity of C430003P19Rik in its signaling context. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that may disrupt PI3K/AKT signaling, potentially causing cells to rely more on alternative signaling pathways that could include C430003P19Rik, thus indirectly enhancing its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor. Its broad-spectrum inhibition may lead to the selective enhancement of C430003P19Rik pathways by inhibiting kinases that normally suppress C430003P19Rik-related signaling processes. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, facilitating the increase of intracellular calcium levels. This increase can activate calcium-dependent signaling pathways that may indirectly enhance the activity of C430003P19Rik. | ||||||